STAT Plus: Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results
ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
The company plans to file a marketing application for the once-daily pill, called tucatinib, with the FDA early next year.
No hay comentarios:
Publicar un comentario